A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence - Report - MDSpire

A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence

  • By

  • Jonathan I. Silverberg

  • Alan D. Irvine

  • Peter Foley

  • James Del Rosso

  • Luis Puig

  • Linda Stein Gold

  • Masahiro Kamata

  • Andreas Wollenberg

  • H. Chih-ho Hong

  • Chia-Yu Chu

  • Yousef Binamer

  • Martin Dossenbach

  • Marta Casillas

  • Gaia Gallo

  • Buelent Akmaz

  • Kim Rand

  • Raj Chovatiya

  • June 17, 2026

  • 0 min

Share

Clinical Report: Evaluating Durability in Atopic Dermatitis Treatments

Overview

Revise to include the importance of treatment adherence in the context of long-term efficacy.

Background

Atopic dermatitis (AD) is a chronic inflammatory skin condition that significantly impacts patients' quality of life. Effective long-term management is crucial, as treatment interruptions are common in real-world settings. Understanding the durability of response to biologic therapies is essential for optimizing treatment strategies and improving patient outcomes.

Data Highlights

Remove the statement about no numerical data; include any relevant statistics or findings.

Key Findings

  • Lebrikizumab shows comparable or superior long-term efficacy compared to dupilumab.
  • Lebrikizumab demonstrates superior efficacy relative to tralokinumab across various treatment adherence levels.
  • The Durability Index (DI) is a novel measure combining on-drug efficacy and off-drug durability of response.
  • Response rates at week 52 differed significantly among the three biologics after treatment withdrawal.
  • This study is the first to apply the DI in an indirect comparative analysis of these treatments.

Clinical Implications

Clinicians should consider the varying efficacy of lebrikizumab, dupilumab, and tralokinumab when developing long-term treatment plans for patients with moderate-to-severe atopic dermatitis. The findings underscore the importance of treatment adherence in achieving sustained therapeutic outcomes.

Conclusion

Highlight the necessity for further validation of the Durability Index in clinical settings.

Related Resources & Content

  1. Dermatology and Therapy, 2026 -- Lebrikizumab ADvocate1 and 2 Monotherapy and ADjoin (Long-Term) Trials: Use of Topicals Therapies
  2. conexiant, 2026 -- Lebrikizumab Meets Phase 3 End Points in Pediatric Atopic Dermatitis
  3. Dermatology and Therapy, 2026 -- Clinical Laboratory Parameters in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52 in the Phase 3 ECZTRA 6 Trial
  4. 2025 Update of AAD Atopic Dermatitis Clinical Guidelines - Guideline Summary - Guideline Central
  5. Dermatology and Therapy — Machine-Learning-Based Prediction of Long-Term Efficacy of Nemolizumab: Post Hoc Analysis of Pooled Data from Two Phase III Clinical Trials
  6. FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
  7. 2025 Update of AAD Atopic Dermatitis Clinical Guidelines - Guideline Summary - Guideline Central
  8. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial - PMC
  9. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2) - PMC
  10. Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2) - PMC
  11. Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison | Dermatology and Therapy | Springer Nature Link
  12. Long-term Outcomes of New Systemic Agents in Atopic Dermatitis: Drug Survival Analyses and Treatment Patterns in Daily Practice - PMC
  13. Recurrence and influencing factors of moderate-to-severe atopic dermatitis after dupilumab withdrawal: a retrospective cohort analysis - PMC

Original Source(s)

A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence

  • by Jonathan I. Silverberg, Alan D. Irvine, Peter Foley, James Del Rosso, Luis Puig, Linda Stein Gold, Masahiro Kamata, Andreas Wollenberg, H. Chih-ho Hong, Chia-Yu Chu, Yousef Binamer, Martin Dossenbach, Marta Casillas, Gaia Gallo, Buelent Akmaz, Kim Rand, Raj Chovatiya

  • June 17, 2026

Related Content

Primary cutaneous adenoid cystic carcinoma of the right forearm: a case report and dermoscopic features

Beyond Drainage: Clinical–Ultrasound Correlation Supports a Broader Definition of the Active Tunnel in Hidradenitis Suppurativa

Association of the inflammatory marker suPAR with chronic pruritus of unknown origin – data from the SOMA.PRU study